



ASX Announcement

US distributor appointed for TorrentX

Sydney, Australia, Thursday, 19 December 2019: Next Science Limited (ASX:NXS) (**Next Science or Company**) announces the execution of a five (5) year exclusive distribution agreement for the sale of its TorrentX Wound Wash in the United States.

Under the agreement, Next Science appoints Tennessee based Triad Life Sciences Inc (**TLS**) to promote, market, distribute and sell TorrentX Wound Wash in the United States for use in wound care for humans including both acute and post-acute settings in the healthcare system. To retain exclusivity, TLS must meet stipulated performance criteria.

TorrentX Wound Wash eliminates microbial activity from most wound sites in approximately 20 seconds. Incorporating Next Science's patented Xbio™ technology, TorrentX is a wound wash for use in places such as emergency rooms, doctors' offices, ambulance/pre-hospital treatment rooms and in-home treatment. It is also suitable for the treatment of any laceration or abrasion and provides a clean wound bed as a preparation for the application of a skin substitute.

TLS is bringing to market a disruptive tissue substitute designed to revolutionise the skin substitute market in both chronic wounds and surgical care. TLS will be pairing TorrentX with this new skin matrix product.

Pending receipt of the FDA 510(k) clearances for TorrentX and for TLS' skin substitute product, TLS will sell the over-the-counter version of TorrentX on a non-exclusive basis alongside Next Science's sales team. Once the FDA 510(k) clearances are received, expected to be Q3 2020, TLS will commence exclusive sales of the paired products under the brand name 'TridentX'.

This announcement has been authorised to be given to ASX by Next Science's Board of Directors.

- - - END - - -

For further information, please contact:

Judith Mitchell, Managing Director

Phone: +61 2 8607 5124

Email: investorqueries@nextscience.com

Michael Brown

Phone: +61 400 248 080

Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and continued commercialisation of its proprietary Xbio technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. For further information visit: www.nextscience.com.